KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Retained Earnings (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Retained Earnings for 13 consecutive years, with $335000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.04% to $335000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $335000.0 through Dec 2025, up 100.04% year-over-year, with the annual reading at $335000.0 for FY2025, 100.04% up from the prior year.
  • Retained Earnings for Q4 2025 was $335000.0 at Xenon Pharmaceuticals, up from -$1.1 billion in the prior quarter.
  • The five-year high for Retained Earnings was $1.3 million in Q3 2024, with the low at -$1.1 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$318.3 million, with a median of -$324.1 million recorded in 2021.
  • The sharpest move saw Retained Earnings surged 145.24% in 2024, then crashed 85438.25% in 2025.
  • Over 5 years, Retained Earnings stood at -$357.4 million in 2021, then crashed by 35.08% to -$482.7 million in 2022, then crashed by 37.78% to -$665.1 million in 2023, then crashed by 35.23% to -$899.5 million in 2024, then skyrocketed by 100.04% to $335000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $335000.0, -$1.1 billion, and $113000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.